Trial Profile
A Randomized, Double-Blinded, Placebo Controlled Study to Evaluate the Tolerability and Safety of Rituximab When Given in Combination With Methotrexate and Etanercept (Enbrel) or Methotrexate and Adalimumab (Humira) in Subjects With Active Rheumatoid Arthritis
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 03 Nov 2021
Price :
$35
*
At a glance
- Drugs Rituximab (Primary)
- Indications Rheumatoid arthritis
- Focus Adverse reactions
- Acronyms TAME
- Sponsors Biogen Idec
- 25 Sep 2015 Status changed from completed to discontinued as reported by ClinicalTrials.gov record.
- 03 Feb 2012 Actual end date (1 Oct 2011 ) added as reported by ClinicalTrials.gov.
- 03 Feb 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.